Aytu BioScience Acquires Commercial-Stage Prostate Cancer Biologic
PR Newswire - Tue Jun 09, 7:00AM CDT
Aytu BioScience, Inc. (OTCMKTS: RSWN), a specialty healthcare company focused on developing treatments for urological and related conditions, today entered into an agreement with Jazz Pharmaceuticals (NASDAQ: JAZZ) to acquire Jazz Pharmaceuticals' rights to ProstaScint®, an imaging agent used to detect the extent and spread of prostate cancer that is marketed in the U.S. ProstaScint's established brand and revenue will enable Aytu to expand its footprint in urology and advance its pipeline of therapeutics and diagnostics.
JAZZ: 178.77 (+2.58)
Rosewind Corporation to Become Aytu BioScience, Inc.
PR Newswire - Tue Jun 02, 7:00AM CDT
Rosewind Corporation (OTCQB: RSWN) announced that, after necessary state filings, the company will be known as Aytu BioScience, Inc., a specialty healthcare company focused on developing treatments for urological and related conditions. The corporate name change was approved by shareholders at a special meeting of Rosewind Corp. shareholders held on June 1, 2015.
Rosewind Corporation to Present at 2015 Marcum MicroCap Conference
PR Newswire - Mon May 18, 7:00AM CDT
Rosewind Corporation (OTCMKTS: RSWN), a specialty healthcare company focused on developing treatments for urological and related conditions, today announced that its Chief Executive Officer, Josh Disbrow and Chief Operating Officer, Jarrett Disbrow, will present at the 2015 Marcum MicroCap Conference being held at the Grand Hyatt New York in New York City.
Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions
PR Newswire - Thu Apr 16, 3:30PM CDT
Rosewind Corporation (OTCMKTS: RSWN) announced today that it has completed a reverse merger with a newly formed specialty healthcare company focused on redox-modulated conditions, with an initial focus on addressing urological disorders. The merged company, which is expected to be re-named Aytu BioScience Inc., has commenced operations and incorporates the pipeline assets of both Vyrix Pharmaceuticals and Luoxis Diagnostics. The Company's strategy is to build a late-stage and commercial pipeline of therapeutics and diagnostics, including its lead therapeutic candidate Zertane(TM), a first-in-class treatment for premature ejaculation (PE) that is nearing commercial-stage, and the RedoxSYS® System, which has CE Marking for Europe and medical device approval by Health Canada and is currently being studied in male infertility.